LitAlert ~~ GeneLit.com

    • Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer.
    • Lee JD, Ryu WJ, Han HJ, Kim TY, Kim MH, Sohn J.
    • Cancers (Basel). 2022 May 13;14(10):2405. doi: 10.3390/cancers14102405.
    • Do Female BRCA2 Pathogenic Variant Carriers Have an Increased Risk of Lung Cancer?
    • Fallet V, Sanchis-Borja M, Benusiglio PR, Cadranel J.
    • J Clin Oncol. 2022 May 12:JCO2200488. doi: 10.1200/JCO.22.00488. Epub ahead of print.

    Letter, Reply:

    Reply to V. Fallet et al.

    Original research:

    Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.

    • Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis.
    • Zhang L, Chen Y, Cheng MY, Zhuang X, Zou J, Wei D, Lin YY, Zhang Y, Wang K.
    • Ther Adv Med Oncol. 2022 May 7;14:17588359221096253. doi: 10.1177/17588359221096253.